ASCs have their limitations, but they are also associated with several benefits for cardiologists and patients alike.

Back in 2024, the FDA advised customers to transition away from the two devices and find alternative treatment options. These most recent recalls focus on a series of maintenance issues that have already been addressed.

According to Heartflow, its AI offering saves health systems nearly $1,400 per patient thanks to reductions in unnecessary cardiovascular testing.